drugset / Trial / NCT04870606
Proxalutamide (GT0918) Treatment for Outpatients With Mild or Moderate COVID-19 Illness
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to assess the efficacy and safety of Proxalutamide (GT0918) as a treatment for outpatients COVID-19 subjects.
Timeline
- Start
- 2021-03-05
- Primary completion
- 2022-01-24
- Completion
- 2022-04-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | PRUXELUTAMIDE | Small molecule | 200 mg | Oral |
Indications
No indication recorded.